Antigen-presenting cell engineering: The molecular toolbox

American Journal of Pathology

Volumn 148, Issue 1, 1996, Pages 1-16

  Tykocinski, Mark L ^a   Kaplan, David R ^a   Medof, M Edward ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL FUNCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; LANGERHANS CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030033419     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (180)

1. Unanue ER, Allen PM The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987, 236:551-557
2. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296
3. Teunissen MB: Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J 1992, 24.697-716
4. Chestnut RW, Grey HM: Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol 1981, 126.1075-1079
5. + T cells to protein antigens in vivo J Immunol 1995, 155 3734-3741
6. Borrello MA, Phipps RP Fibroblasts support outgrowth of splenocytes simultaneously expressing B lymphocyte and macrophage characteristics J Immunol 1995, 15:4155-4161
7. Rott O, Tontsch U, Fleischer B: Dissociation of antigen-presenting capacity of astrocytes for peptide-antigens versus superantigens J Immunol 1993, 150 87-95
8. + T cell proliferation in vitro. J Immunol 1995, 154 151-161
9. Hughes CCW, Savage COS, Pober JS: Endothelial cells augment T cell interleukin-2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med 1990, 171.1453-1467
10. + T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med 1992, 176:1291-1302
11. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells J Immunol 1992, 149.661-667
12. Del Pozo V, De Andrés B, Martín E, Cardaba B, Fernandez JC, Gallardo S, Tramon P, Leyva-Cobian F, Palomino P, Lahoz C. Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridomas by eosinophils after antigen processing. Eur J Immunol 1992, 22:1919-1925
13. Hewitt CRA, Feldman M: Human T cell clones present antigen. J Immunol 1989, 142.1429-1436
14. Sidhu S, Deacock S, Bal V, Batchelor JR, Lombardi G, Lechler RI: Human T cells cannot act as autonomous antigen-presenting cells, but induce tolerance in antigen-specific, and alloreactive responder cells J Exp Med 1992, 176.875-880
15. Spaner D, Cohen BL, Miller RG, Phillips RA. Antigen-presenting cells for naive transgenic γδ T cells. Potent activation by activated αβ T cells J Immunol 1995, 155:3866-3876
16. Lorenz RG, Allen PM: Thymic cortical epithelial cells can present self-antigens in vivo. Nature 1989, 337: 560-562
17. Pober JS, Gimbrone MA, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA: Ia expression by vascular endothelium is inducible by activated T cells and human γ interferon. J Exp Med 1983, 157:1339-1353
18. Geppert TD, Lipsky PE. Antigen presentation by interferon-γ-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. J Immunol 1985, 135 3750-3762
19. St. Louis JD, Lederer JA, Lichtman AH. Costimulator deficient antigen presentation by an endothelial cell line induces a nonproliferative T cell activation response without anergy. J Exp Med 1993, 178:1597-1605
20. Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J, Lechler R: Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990, 20:1893-1897
21. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet 1991, 337(8735) 211-214
22. Fierz W, Endler B, Reske K, Wekerle H, Fontana A: Astrocytes as antigen presenting cells. I Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 1985, 134:3785-3793
23. Takiguchi M, Frelinger JA: Induction of antigen presentation ability in purified cultures of astroglia by interferon-γ. J Mol Cell Immunol 1986, 2:269-280
24. Sedgwick J, Mössner R, Schwender D, Ter Meulen V: Major histocompatibility complex-expressing nonhematopoietic astroglial cells prime only CD8 T lymphocytes: astroglial cells as perpetuators but not initiators of CD4 T cell responses in the central nervous system J Exp Med 1991, 173:1235-1246
25. Frei K, Siepl C, Groscurth P, Bodmer S, Schwerdel C, Fontana A Antigen presentation and tumor cytotoxicity by interferon-γ treated microglial cells. Eur J Immunol 1987, 17 1271-1278
26. Hickey WF Kimura H. Perivascular microglial cells of the CNS are bone-marrow derived and present antigen in vivo Science 1988, 239:290-292
27. Zhang Y, Porter S, Wekerle H. Schwann cells and myasthenia gravis: preferential uptake of soluble and membrane bound AchR by normal and immortalized Schwann cells, and immunogenic presentation to AchR-specific T line lymphocytes. Am J Pathol 1990, 136.111-122
28. Percopo CM, Hooks JJ, Shinohara T, Caspi R, Detrick B: Cytokine-mediated activation of a neuronal retinal resident cell provokes antigen presentation J Immunol 1990, 145.4101-4107
29. + lymphocytes by syngeneic brain microvascular smooth muscle cells. J Immunol 1990, 145:1099-1104
30. Alsalameh S, Jahn B, Krause A, Kalden JR, Burmester GR: Antigenicity and accessory cell function of human articular chondrocytes. J Rheumatol 1991, 18 414-421
31. Bland PW, Whiting CV: Antigen processing by isolated rat intestinal villus enterocytes. Immunology 1989, 68:497-502
32. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983, 2(8359):1115-1119
33. + T cells. J Clin Invest 1994, 93 1208-1215
34. Kündig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, Zinkernagel RM: Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1349
35. Marrack P, Kappler J The staphylococcal enterotoxins and their relatives. Science 1990, 248.705-711
36. + T cells Nature 1994, 372:691-694
37. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Soriano T, Brenner MB, Kronenberg M, Brennan PJ, Modlin RL: CD1-restricted T-cell recognition of microbial lipoglycan antigens. Science 1995, 269 227-230
38. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160 1558-1578
39. Lederman MM, Purvis SF, Walter EI, Carey JT, Medof ME Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of DAF Proc Natl Acad Sci USA 1989, 86 4205-4209
40. Ferguson MAJ, Williams AF: Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures Annu Rev Biochem 1988, 57 285-320
41. Thomas JR, Dwek RA, Rademacher TW. Structure, biosynthesis, and function of glycosylphosphatidylinositols. Biochemistry 1990, 29.5413-5422
42. Englund PT: The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993, 62:121-138
43. Medof ME, Nagarajan S, Tykocinski ML Cell surface engineering with GPI-anchored proteins. FASEB J 1996 (in press)
44. Medof ME, Walter EI, Rutgers JL, Knowles D, Nussenzweig V: Identification of the decay-accelerating factor (DAF) on epithelial glandular cells and in body fluids. J Exp Med 1987, 165 848-864
45. Walter EI, Roberts WL, Rosenberry TL, Ratnoff WD, Medof ME Structural basis for variations in the sensitivity of human decay-accelerating factor to phosphoinositol-specific phospholipase C cleavage. J Immunol 1990, 144:1030-1036
46. Roberts WL, Myher JJ, Kukis A, Low MG, Rosenberry TL: Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase Palmitoylation of inositol results in resistance to phosphoinositol-specific phospholipase C. J Biol Chem 1988, 263.18766-18775
47. Walter EI, Ratnoff WD, Long KE, Kazura JW, Medof ME: Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accerating factor protein in cells. J Biol Chem 1992, 261:356-362
48. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML: Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement Proc Natl Acad Sci USA 1987, 84:2007-2011
49. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW, Nussenzweig V: Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins Nature 1987, 325.545-549
50. Tykocinski ML, Shu HK, Ayers DJ, Walter EI, Getty RR, Groger RK, Hauer CA, Medof ME Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci USA 1988, 85:3555-3559
51. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin Jr DW: Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science 1987, 238:1280-1283
52. Huang J-H, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML: Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis Immunity 1994 1 607-613
53. Davis SJ, Ward HA, Puklavec MJ, Willis AC, Williams AF, Barclay AN. High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants J Biol Chem 1990, 265 10410-10418
54. Sherr DH, Cheung N-K, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. II. T cell-mediated nonresponsiveness to fowl γ-globulin J Immunol 1979, 122: 1899-1904
55. Colsky AS, Stein-Streilein J, Peacock JS: Surrogate receptor-mediated cellular cytotoxicity a method for "custom designing" killer cells of desired target specificity J Immunol 1988, 140.2515-2519
56. Colsky AS, Peacock JS: Palmitate-derivatized antibodies can function as surrogate receptors for mediating specific cell-cell interactions J Immunol Methods 1989, 124:179-187
57. Kim SA, Peacock JS: The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions. J Immunol Methods 1993, 158:57-65
58. Wilcox CA, Olson EN: The majority of cellular fatty acid acylated proteins are localized to the cytoplasmic surface of the plasma membrane. Biochemistry 1987, 26 1029-1036
59. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G Determinant spreading and the dynamics of the autoimmune T cell repertoire. Immunol Today 1993, 14(5).203-208
60. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller, A. Moudgil K. Dominance and crypticity of T cell antigenic determinants Annu Rev Immunol 1993, 11:729-766
61. Coeshott C, Grey HM. Transfer of antigen-presenting capacity to Ia-negative cells upon fusion with Ia-bearing liposomes. J Immunol 1985, 134:1343-1348
62. Huang JH, Greenspan NS, Tykocinski ML Alloantigenic recognition of artificial glycosylphosphatidylinositol-anchored HLA-A2 1 Mol Immunol 1994, 31. 1017-1028
63. Mottez E, Langlade-Demoyen P, Gournier H, Martinon F, Maryanski J, Kourilsky P, Abastado J-P: Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. J Exp Med 1995, 181:493-502
64. Lee L, McHugh L, Ribaudo RK, Kozlowski S, Margulies DH, Mage MG: Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active β 2-microglobulin domain. Eur J Immunol 1994, 24.2633-2639
65. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling GJ, Arnold B: Levels of peripheral T cell tolerance induced by different doses of tolerogen Science 1994, 263 674-676
66. Pelfrey CM, Tranquill LR, Boehme SA, McFarland HF, Lenardo MJ: Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals. J Immunol 1995, 154.6191-6202
67. Eberl G, Roggero MA, Corradin G A simple mathematical model for the functional peptide/MHC/TCR interactions. J Immunol 1995, 154 219-225
68. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht H-J, Vitiello A, Chestnut R, Person JL, Redeker AG, Chisari FV: HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993, 150 4659-4671
69. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180.347-352
70. Peoples GE, Goedegebuure PS, Smith R, Lihehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995, 92:432-436
71. Ostrand-Rosenberg S. Tumor immunotherapy, the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994, 6:722-727
72. Houghton AN Cancer antigens: immune recognition of self and altered self J Exp Med 1994, 180:1-4
73. Boon T, Cerottini J, Van den Eynde B, van der Bruggen P, Van Pel A Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994, 12:337-365
74. Lotze MT, Finn OJ: Cellular immunity and the immunotherapy of cancer. J Immunotherapy 1993, 14. 79-87
75. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway a means to induce tolerance Curr Opin Immunol 1994, 6.797-807
76. Koeppen H, Singh S, Schreiber H: Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Ann NY Acad Sci 1993, 690:244-255
77. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells Curr Opin Immunol 1992, 4:619-623
78. Blankenstein T, Rowley DA, Schreiber H: Cytokines and cancer: experimental systems. Curr Opin Immunol 1991, 3.694-698
79. Colombo M, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy where are we now? Immunol Today 1994, 15 48-51
80. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an immune response. Cell 1990, 60.397-403
81. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT: Cancer immunotherapy of established tumors with IL-12. effective delivery by genetically engineered fibroblasts J Immunol 1995, 155 1393-1403
82. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4 Cell 1992, 71.1093-1102
83. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher L. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules Proc Natl Acad Sci USA 1993, 90 5687-5690
84. + T cells by B7-transfected melanoma cells Science 1993, 259:368-370
85. Townsend, SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994, 54:6477-6483
86. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom K. Tumor immunogenicity determine the effect of B7 costimulation on T cell mediated tumor immunity. J Exp Med 1994, 179:523-532
87. + T lymphocytes by B7, a natural ligand for CD28, can be utilized to treat established mouse melanoma J Immunol 1994, 153.421-428
88. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994, 54.5552-5555
89. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994, 179:1205-1214
90. Yang G, Hellstrom KE, Mizuno MT, Chen L: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation J Immunol 1995, 155:3897-3903
91. Yang G, Hellstrom KE, Hellstrom I, Chen L Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995, 154.2794-2800
92. Lukacs KV, Lowrie DB, Stokes RW, Colston MJ Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J Exp Med 1993, 178:343-348
93. Trojan J, Blossey BK, Rudin SD, Tykocinski ML, Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I Proc Natl Acad Sci USA 1992, 89 4874-4878
94. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense IGF-1 RNA Science 1993, 259.94-97
95. Trojan J, Johnson TR, Rudin SD, Blossey BK, Kelley KM, Shevelev A, Abdul-Karim FW, Anthony DD, Tykocinski ML, Ilan J, Ilan JO: Gene therapy of murine teratocarcinoma: separate functions for IGF-I and IGF-II in immunogenicity and differentiation. Proc Natl Acad Sci USA 1994, 91.6088-6092
96. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994, 54: 2218-2222
97. Baserga R. The insulin-like growth factor I receptor, a key to tumor growth? Cancer Res 1995, 55:249-252
98. Dorigo O, Shawler DL, Royston I, Sobol RE, Fahrai H. Transforming growth factor β (TGFβ) inhibits effect of IL-2 gene therapy in TGFβ producing tumors (San Diego, CA) AACR Eighty-sixth Annual Meeting, March 18-22, 1995, Toronto, Ontario, Canada
99. Hauer C, Getty RR, Tykocinski ML: Epstein-Barr virus episome-based expression in human myeloid leukemia cells. Nucleic Acids Res 1989, 17.1989-2003
100. Groger RK, Morrow D, Tykocinski ML. Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors. Gene 1989, 81 285-294
101. Hambor JE, Hauer CA, Shu HK, Groger RK, Kaplan DR, Tykocinski ML: Use of an EBV virus episomal replication for antisense RNA-mediated gene inhibition in human cytotoxic T cell clone Proc Natl Acad Sci USA 1988, 85 4010-4014
102. Liu Y, Linsley P. Costimulation of cell growth Curr Opin Immunol 1992, 4:265-270
103. Bellone M, Iezzi G, Manfredi AA, Protti MP, Dellabona P, Casorati G, Rugarli C: In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 1994, 24:2691-2698
104. Green, JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994, 1:501-508
105. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995, 155.5498-5505
106. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P: Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80) Proc Natl Acad Sci USA 1995, 92: 8059-8063
107. + T lymphocytes. J Immunol 1994, 152 1523-1531
108. Bell GM, Imboden JB. CD2, and the regulation of T cell anergy. J Immunol 1995, 155:2805-2807
109. Menu E, Tsai BC, Bothwell ALM, Sims PJ, Bierer BE: CD59 costimulation of T cell activation. CD58 dependence, and requirement for glycosylation J Immunol 1994, 153 2444-2456
110. Liu Y, Jones B, Aruffo A, Sullivan KM, Linsley PS, Janeway CA Jr. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth J Exp Med 1992, 175:437-445
111. + T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles. J Immunol 1994, 153:2479-2487
112. Kroesen B-J, Bakker A, van Lier RAW, The HT, de Leij L: Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res 1995, 55:4409-4415
113. Kaplan DR: Solid phase interleukin 2. Mol Immunol 1991, 28.1255-1261
114. Bergman CA, Gould DL, Kaplan DR. Cytometrically detected specific binding of interleukin 2 to cells Cytokine 1992, 4:192-200
115. Kaplan DR. Delivery of interleukin 2 for immunotherapy. J Chromatogr Biomed Appl 1994, 662:315-323
116. Kaplan DR, Smith D, Huang R, Yildirim Z Self-association of interleukin 2 bound to its receptor. FASEB J 1995, 9.1096-1102
117. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M-S: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells Science 1994, 263 518-520
118. Kubin M, Kamoun M, Trinchieri G Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation, and cytokine production of human T cells. J Exp Med 1994, 180:211-222
119. Murphy EE, Terres G, Macatonia SE, Hseih C, Mattson J, Lanier L, Wysocka M, Trinchieri G, Murphy K, O'Garra A B7 and IL-12 cooperate for proliferation, and IFN-γ production by mouse helper T clones that are unresponsive to B7 costimulation. J Exp Med 1994, 180.223-231
120. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL B7-1, and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995, 55.4980-4987
121. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L: Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases Cancer Res 1995, 55 4941-4949
122. Martin DR, Miller RG In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J Exp Med 1989, 170 679-690
123. Fink PJ, Shimenkovitz RP, Bevan MJ: Veto cells. Annu Rev Immunol 1988, 6.115-137
124. Rammensee H-G Veto function in vitro and in vivo. Intern Rev Immunol 1989, 4:175-191
125. Kaplan DR, Hambor JE, Tykocinski ML: An immunoregulatory function for the CD8 molecule. Proc Natl Acad Sci USA 1989, 86:8512-8515
126. Hambor JE, Weber MC, Tykocinski ML, Kaplan DR: Regulation of allogeneic responses by expression of CD8 α chain on stimulator cells. Int Immunol 1990, 2:879-883
127. + cells. J Immunol 1990, 145: 1646-1652
128. Tykocinski ML, Kaplan DR. A multifunctional perspective of the CD8 molecule. NK Cell Mediated Cytotoxicity Receptors, Signaling and Mechanisms. Edited by E Lotzova, RB Herberman. Ann Arbor, CRC Press, 1992, pp 393-408
129. Tykocinski ML, Kaplan DR: CD8-dependent immunoregulation: prospects for anti-rejection therapies based upon CD8 modification of alloantigen-presenting cells. Kidney Int 1993, 43(Suppl 39). S120-S123
130. 3 domain of class I MHC Science 1991, 252:1424-1427
131. + cells in the induction of peripheral tolerance. J Immunol 1994, 152:2222-2228
132. Smith DM, Bluestone JA, Jeyarajah DR, Newberg MH, Engelhard VH, Thistlethwaite JR, Woodle ES: Inhibition of T cell activation by a monoclonal antibody reactive against the α3 domain of human MHC class I molecules. J Immunol 1994, 153:1054-1067
133. Vremec D, Zorbas M, Scollay R, Saunders DJ, Ardavin CF, Wu L, Shortman K: The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells J Exp Med 1992, 176: 47-58
134. Fast LD: Generation and characterization of IL-2-activated veto cells. J Immunol 1992, 149 1510-1515
135. Vitiello A, Heath WR, Sherman LA. Consequences of self-presentation of peptide antigen by cytolytic T lymphocytes J Immunol 1989, 143.1512-1517
136. + T cells Science 1990, 248: 1643-1646
137. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice potential implications for marrow transplantation in humans. J Exp Med 1993, 178.703-712
138. + cytotoxic T lymphocytes is due to fratricide J Immunol 1993, 151.658-667
139. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994, 84.2436-2446
140. Critchfield JM, Boehme SA, Lenardo MJ: The regulation of antigen-induced mature T cell apoptosis Apoptosis and the Immune Response. Edited by C Gregory. New York, John Wiley & Sons, 1994, pp 55-114
141. Majno G, Joris I: Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol 1995, 146:3-15
142. Steller H: Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449
143. Nagata S, Goldstein P The Fas death factor. Science 1995, 267:1449-1456
144. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage J Immunol 1995, 154:3806-3813
145. Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993, 90.4409-4413
146. + T cells responding to a bacterial superantigen J Immunol 1995, 154:4302-4308
147. Wong GHW, Goeddel DV: Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways J Immunol 1994, 152:1751-1755
148. Waanders GA, Shakhov AN, Held W, Karapetian O, Acha-Orbea H, MacDonald HR Peripheral T cell activation, and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med 1993, 177. 1359-1366
149. Webb SR, Hutchinson J, Hayden K, Sprent J: Expansion/deletion of mature T cells exposed to endogenous superantigens in vivo. J Immunol 1994, 152:586-597
150. Ben-Nun A Staphylococcal enterotoxin B as a potent suppressant of T cell proliferative responses in rats Eur J Immunol 1991, 21:815-818
151. Theobald VA, Lauer JD, Kaplan FA, Baker KB, Rosenberg M: "Neutral allografts" lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens Transplantation 1993, 55 128-133
152. Londei M, Lamb JR, Bottazzo GF, Feldmann M: Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned T cells Nature 1984, 312 639-641
153. Ellison Ca, MacDonald GC, Rector ES, Gartner JG: γδ T cells in the pathobiology of murine acute graft-versus-host disease: evidence that γδ T cells mediate natural killer-like cytotoxicity in the host and that elimination of these cells from donors significantly reduces mortality. J Immunol 1995, 155 4189-4198
154. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lainer LL. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol 1995, 155.2306-2310
155. Rajagopalan S, Winter CC, Wagtmann N, Long EO The Ig-related killer cell inhibitory receptor binds zinc and requires zinc for recognition of HLA-C on target cells J Immunol 1995, 155:4143-4146
156. Weber MC, Groger RK, Tykocinski ML. A glycosylphosphatidylinositol-anchored cytokine can function as an artificial cellular adhesin Exp Cell Res 1994, 145:1646-1652
157. Finberg RW, White W, Weller N Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992, 149:2055-2060
158. Brodsky RA, Jane SM, Vanin EF, Mitsuya H, Peters TR, Shimada T, Medof ME, Nienhuis AW. Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer. Hum Gene Ther 1994, 5:1231-1239
159. Ashwell JD, Jenkins MK, Schwartz RH: Effect of γ irradiation on resting B lymphocytes. II. Functional characterization of the antigen-presenting defect J Immunol 1988, 141:2536-2544
160. Gajewski TF, Pinnas M, Wong T, Fitch FW: Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations J Immunol 1991, 146.1750-1758
161. Croft M. Activation of naive, memory, and effector T cells. Curr Opin Immunol 1994, 6:431-437
162. Elias D, Reshef T, Birk OS, Van der Zee R, Walker MD, Cohen IR: Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991, 88.3088-3091
163. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J: MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993, 261:1451-1454
164. Maron R, Zerubavel R, Friedman A, Cohen IR. T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol 1983, 131:2315-2322
165. Chiocchia G, Manoury-Schwartz B, Boissier MC, Gahery H, Marche PN, Fournier C. T cell regulation of collagen-induced arthritis in mice. III Is T cell vaccination a valuable therapy? Eur J Immunol 1994, 24. 2775-2783
166. + cytotoxic T cell clones A novel potentially immunoregulatory T-T cell interaction in man. J Exp Med 1990, 171: 2011-2024
167. Moss DJ, Burrows SR, Baxter GD, Lavin MF T cell-T cell killing is induced by specific epitopes, evidence for an apoptotic mechanism J Exp Med 1991, 173. 681-686
168. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994, 76:275-285
169. Jenkins MK: The ups and downs of T cell costimulation Immunity 1994, 1:443-446
170. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159
171. Valle A, Aubry JP, Durand I, Banchereau J: IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counter-structure to T cell CD28: an amplification mechanism for T-B interactions. Int Immunol 1991, 3:229-235
172. Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW: IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 1994, 152:5723-5733
173. Ding L, Linsley PS, Huang L-Y, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993, 151:1224-1234
174. Villanueva POF, Reiser H, Stadecker MJ: Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. Effect on expression of B7 and B7-2 costimulatory molecules by macrophages. J Immunol 1994, 153:5190-5199
175. Czarniecki CW, Chiu-HH, Wong-GH, McCabe-SM, Palladino-MA: Transforming growth factor β-1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988, 140:4217-4223
176. Honda S, Campbell JJ, Andrew DP, Engelhardt B, Butcher VA, Warnock RA, Ye RD, Butcher EC: Ligand-induced adhesion to activated endothelium and to vascular cell adhesion molecule-1 in lymphocytes transfected with the N-formyl peptide receptor. J Immunol 1994, 152.4026-4035
177. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB: Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995, 155:1165-1174
178. Yin D, Fathman CG: Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4 Ig J Immunol 1995, 155:1655-1659
179. Fayen J, Huang JH, Meyerson H, Zhang D, Getty R, Greenspan N, Tykocinski M: Class I MHC α 3 domain can function as an independent structural unit to bind CD8α Mol Immunol 1995, 32:267-275
180. Meyerson HM, Huang J-H, Fayen JD, Tsao H-M, Getty RR, Greenspan NS, Tykocinski ML: Functional dissociation of CD8α's immunoglobulin homologue and connecting peptide domains. J Immunol 1996 (in press)